BLOG

Macrophages are also known to play a critical role in anti-tumor immunity. They can infiltrate into tumors and are found in most tumor sites. Generally, it is considered that GcMAF increases phagocytic activity, and superoxide radical generation, and has anti-angiogenic and anti-tumor effects. We have also observed that GcMAF increases the number of monocytes in the blood and increases the rate of maturation of Dendritic cells in vitro according to the experiments done by Dr. Kubo at Saisei Mirai.   Phagocytosis assay with Second Generation GcMAF. Photo, University of Tokushima.

GcMAF is Gc protein-derived Macrophage Activating Factor.      Basics of Gc protein and GcMAF What is Gc protein? Gc protein is short for Group-specific Component Protein, also known as Vitamin D-binding protein. It is a glycoprotein of about 56kDa (in size), present in human serum. It is a member of the albumin superfamily. Gc protein works as a vitamin D carrier protein and also scavenges G-actin released by cell lysis. Gc protein is the precursor of the most powerful macrophage activating factor (GcMAF).   There are six major subtypes of Gc protein, including the homodimers and heterodimers of Gc1f,...

  The key concept of cancer therapy is the destruction of local cancer tissue in combination with immunotherapy. It is important that we destroy local cancer tissue with minimal side effects and kill cancer cells selectively. In this meaning, Sondynamic therapy, Ultrasound guided HIFU and Tumor-treating field therapy in combination with GcMAF based Immunotherapy seem to be very promising.

Saisei Mirai has developed the 2nd and 3rd Generation GcMAF in Japan. We hold worldwide patents. We have clinics in Osaka, Kobe, and Tokyo.  Our head office and cell processing center are in Osaka.     We have been mainly treating cancer patients in the past, but we now treat patients with a wide variety of diseases from all over the world.   Saisei Mirai is expanding overseas and now has several branches around the world. Our goal is to help cure serious diseases, such as cancer, autism, and infectious diseases.   Saisei Mirai is conducting joint research with 6 universities...